Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

Influence of Mitroflow bioprosthesis structural valve deterioration on cardiac morbidity

Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review


  1. Trileaflet semilunar valve reconstruction: pulsatile in vitro evaluation

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  2. Hybridbehandling af proteintabende enteropati hos patient med univentrikulærtkredsløb

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  3. Comparison of Outcome in Patients With Familial Versus Spontaneous Atrial Septal Defect

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  • Farhad Waziri
  • Zarmiga Karunanithi
  • Brian Bridal Løgstrup
  • Vibeke Hjortdal
  • Per Hostrup Nielsen
  • Steen Hvitfeldt Poulsen
Vis graf over relationer

BACKGROUND: This study investigated the extent and nature of cardiac morbidity and cause of mortality in patients with Mitroflow structural valve deterioration (SVD).

METHODS: A retrospective study was performed examining the medical records of patients who had received Mitroflow bioprosthesis between February 2001 and April 2014 and died during this period. A total of 211 patients were identified and included in the analyses. To determine the cause of mortality, cases were divided into three predefined groups: cardiovascular death due to SVD (group 1), cardiovascular death with no SVD (group 2) and non-cardiovascular death without SVD (group 3).

RESULTS: Overall mortality in this study was 7.6% at 1 year, 46.4% at 5 years and 97.2% at 10 years. In group 1, 53 patients (25%) died; in group 2, 59 patients (28%) died; and in group 3, 99 patients (47%) died. Hospitalisation for congestive heart failure was observed in 49.1% in the SVD group vs. 10.2 and 13.1% in the two other groups, p < 0.001. Hospitalisation for endocarditis was also significantly higher in the SVD group (11.3%) than in the two other groups (6.8 and 0%), p < 0.05. Hospitalisation due to myocardial infarction, cerebral stroke, arrhythmia or other cardiac-related diseases was not significantly different between groups.

CONCLUSION: Structural valve deterioration in Mitroflow bioprosthesis was associated with a high prevalence of hospital admissions due to congestive heart failure and endocarditis. Patients with Mitroflow bioprosthesis should be systematically and routinely followed with echocardiography, and reoperation should be considered if SVD has developed.

TidsskriftJournal of Cardiothoracic Surgery
Udgave nummer1
Sider (fra-til)62
StatusUdgivet - 18 mar. 2019
Eksternt udgivetJa

ID: 59546764